Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Effect of a local anesthetic lozenge in relief of symptoms in burning mouth syndrome

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Prevalence, type distribution, and risk factors for oral HPV in Danish renal transplant recipients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Workshop of European task force on medication-related osteonecrosis of the jaw-Current challenges

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Management of patients with ocular manifestations in vesiculobullous disorders affecting the mouth

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Characteristics of patients with COVID-19 pneumonia at Hvidovre Hospital, March-April 2020

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. High suPAR and Low Blood Eosinophil Count are Risk Factors for Hospital Readmission and Mortality in Patients with COPD

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

OBJECTIVE: Patients with burning mouth syndrome (BMS) often represent a clinical challenge as available agents for symptomatic treatment are few and often ineffective. The aim was to evaluate the effect of a bupivacaine lozenge on oral mucosal pain, xerostomia and taste alterations in patients with BMS.

METHODS: Eighteen 18 patients (4 men and 14 women) aged 39-71 years with BMS were included in this randomized, double-blinded, placebo-controlled, cross-over trial. Lozenges (containing bupivacaine or placebo) were administrated three times a day for two weeks for two separate treatment periods. Assessment of oral mucosal pain, xerostomia and taste alterations was performed in a patient diary on a visual analogue scale (ranging from 0-100 mm) before and after the lozenge was dissolved.

RESULTS: The bupivacaine lozenge significantly reduced the burning oral pain (p<0.001), increased the sense of taste disturbances (p<0.001), and had no impact on xerostomia, when adjusted for the treatment period.

CONCLUSIONS: Our results indicate that the bupivacaine lozenge offers a novel therapeutic modality to patients with BMS, although without alleviating effect on the associated symptoms, taste alterations and xerostomia. This article is protected by copyright. All rights reserved.

OriginalsprogEngelsk
TidsskriftOral Diseases
Vol/bind22
Udgave nummer2
Sider (fra-til)123-131
ISSN1354-523X
DOI
StatusUdgivet - mar. 2016

ID: 45832675